PPDI Pharmaceutical Prod Dev (MM)

Today, www.EquityMarketsInc.com announced its research report highlighting Human Genome Sciences (NASDAQ: HGSI) and Pharmaceutical Product Development, Inc. (NASDAQ: PPDI). Full content and research is available at www.EquityMarketsInc.com/research.php?id=HGSI+PPDI.

Short-term outlooks within US and global economies continue to adjust downward, as US Treasury yields touched their lowest levels in over 65 years. International Monetary Fund downgraded estimates for US growth by 1.0% this year, down from 2.5%. 'Significant downside risks' to the US economy were confirmed by the Federal Reserve pressured by 'strains in global financial markets.'

As the US dollar trades above an eight-month high against the Euro, it highlights a deepening of the Eurozone sovereign debt crisis -- furthered by continued policy inaction from European governments. We expect continued volatility until economic data stabilizes and we see decisive policy action to deal with the Eurozone debt crisis.

Our members are preparing for a turn in tides. Currently, the Credit Suisse Risk Appetite Indicator is at a 30-year low. For the past three occurrences, this level has acted as a leading indicator of large stock market rallies 18 months following.

Equity Markets has reviewed Human Genome Sciences for its current position within the healthcare industry. Human Genome Sciences, Inc. (HGS) is a biopharmaceutical company. The Company's products are BENLYSTA (belimumab) for systemic lupus erythematosus (SLE) and raxibacumab for inhalation anthrax. GlaxoSmithKline (GSK) is a HGS partner in the co-development and commercialization of BENLYSTA. The full research report on Human Genome Sciences (NASDAQ: HGSI) is available here: www.EquityMarketsInc.com/research.php?id=HGSI.

Equity Markets has reviewed Pharmaceutical Product Development, Inc. for its development within the healthcare industry. Pharmaceutical Product Development, Inc. (PPD) is a global contract research organization providing drug discovery, development and lifecycle management services. The Company's clients and partners include pharmaceutical, biotechnology, medical device, academic, non-profit and government organizations. The full research report on Pharmaceutical Product Development, Inc. (NASDAQ: PPDI) is available here: www.EquityMarketsInc.com/research.php?id=PPDI.

About Equity Markets Our mission at Equity Markets is to be the best source of content and research, while educating, enlightening and informing investors. Equity Markets combines street smart analysts and professional market researchers to provide investors with detailed company profiles and market coverage.

Contact: Samuel Littman Email Contact www.EquityMarketsInc.com